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Abstract Several complications of
advanced diabetic retinopathy can be
treated surgically. Vitrectomy can
clear media opacities, relieve traction
on the retina, and makes adequate
laser treatment of the retina possible.
Removal of premacular vitreous may
also improve diabetic macular ede-
ma. Instrumentation, understanding
of the pathophysiology, surgical
skills as well as supplementary
pharmacotherapy have improved
surgical results. Indications and tim-
ing for surgery have considerably
changed in the past decades and the
threshold for surgery has been con-
tinuously lowered, as vitrectomy be-
came safer. The primary disease of
the retinal microvasculature with
capillary occlusion and retinal isch-
emia is still the limiting factor, re-
sponsible for disappointing functional
results in anatomically successfully
operated eyes.
Introduction
Early documented attempts at vitreous surgery date back
to Albrecht von Graefe in 1863 [11]. He predicted a vast
field for surgical expertise in the future. It took a century
to come up to his expectations, when in 1970 the first
successful pars plana vitrectomy was performed by Ma-
chemer in an eye with diabetic vitreous hemorrhage [21].
Complications of proliferative diabetic retinopathy were
then and still are important indications for vitreous sur-
gery [9, 28].
In the meantime the introduction of laser therapy [18,
23] and the implementation of good metabolic control
evolved as effective strategies to prevent the development
of severe stages of diabetic retinopathy [5, 30]. Never-
theless, a considerable number of eyes still progress and
may become candidates for surgery. Progression of reti-
nopathy may occur despite optimal treatment or because
adequate therapy was not available.
Vitreous surgery addresses several problems of ad-
vanced diabetic retinopathy. Media opacities can be re-
moved and tractively elevated retina reattached. More-
over, removal of the vitreous has a stabilizing effect on
the subsequent development of the proliferative process.
In a vitrectomized eye there is no anatomical scaffold
which could be used as a matrix for ingrowth of fibro-
vascular tissue into the eye. Relief of traction on retinal
vessels may also improve blood flow within these vessels
and reduce leakage. In addition, unrestricted circulation
of fluid in the vitreous cavity after vitrectomy seems to
improve the oxygen supply to the inner retina and pre-
vents accumulation of vasoactive cytokines in the retina.
In eyes with vitreous hemorrhage or tractional elevation
of the retina it is often not possible to apply the necessary
laser treatment to the retina. Intraoperative endolaser co-
agulation may therefore stabilize the proliferative process
[9, 28]. This review focuses on indications for vitreous
surgery in proliferative diabetic retinopathy and on in-
traoperative strategies to avoid complications specific to
vitreous surgery in diabetic retinopathy.
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Indications for surgery
Media opacities
Posterior segment neovascularizations mainly occur in
eyes with an attached vitreous. Fibrovascular prolifera-
tions grow along the vitreoretinal interface and induce
contraction and partial detachment of the vitreous. This
contraction may tear the new vessels, leading to vitreous
and subhyaloidal hemorrhage. Initially ophthalmologists
recommended waiting 6–12 months before considering
surgery for diabetic vitreous hemorrhage. The Diabetic
Retinopathy Vitrectomy Study (DRVS) showed a clear
benefit of early surgery for type 1 diabetics, who tend to
develop more aggressive fibrovascular proliferations [6].
These eyes often experience progressive tractive com-
plications while the retina cannot be visualized due to the
vitreous hemorrhage. B-scan ultrasonography is an ex-
cellent tool for the detection of tractive fibrovascular
membranes beneath the hemorrhage. These eyes require
early surgery, while eyes without retinal traction may be
followed for spontaneous clearing of the hemorrhage.
Extensive subhyaloidal hemorrhage (Fig. 1) indicates an
intact posterior hyaloid that may serve as an scaffold for
further fibrovascular proliferations. Early surgery is rec-
ommended in these cases.
In eyes with vitreous hemorrhage and anterior segment
neovascularizations, waiting for clearance of the hemor-
rhage may cause irreversible damage. Therefore, vitrec-
tomy with intraoperative laser therapy should be per-
Fig. 1 a Dense subhyaloidal hemorrhage in an eye with extensive
fibrovascular membranes. In the area without subhyaloidal blood
the vitreous and the fibrovascular membranes are firmly attached to
the retina, preventing penetration of blood between retina and vit-
reous. b After vitreous surgery with removal of the membranes and
endolaser, the retina is flat and extensive subretinal exudates due to
tractive retinal edema are visible. c One year later the exudates are
completely reabsorbed and VA has increased to 0.4
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formed early before irreversible obstruction of the cham-
ber angle by fibrovascular tissue and neovascular glau-
coma develops.
Other media opacities such as synchisis nivea may
prevent adequate fundus visualization and a necessary
laser treatment. Surgical removal of the vitreous opacities
and endolaser treatment may be preferred to allow ade-
quate control of the retinopathy [15].
Photocoagulation of the retina may not be possible in
eyes with dense cataract, synechia, miosis, and active
anterior or posterior segment neovascularizations. Per-
forming only cataract surgery may even aggravate the
neovascular process. In this situation combined cataract
and vitreous surgery allowing adequate intraoperative
laser therapy may be considered [2]. Alternatively, es-
pecially in cases with iris rubeosis, transscleral cry-
otreatment to the peripheral retina may be chosen to
stabilize the anterior segment neovascular process before
cataract surgery is performed [25]. Although some au-
thors advocate routine retinal cryoablation several weeks
before vitrectomy in diabetic eyes, this strategy is not
generally recommended because of the intraocular in-
flammatory trauma induced by extensive cryotreatment
[16].
Vitreoretinal traction
Tractional retinal detachment is not generally an urgent
indication for surgery. Tractional retinal detachment
with fibrotic, non-vascularized membranes outside of the
macular region, especially nasally to the disc may be
safely observed. Only 14% of eyes with extramacular
tractional retinal detachment experienced a loss of vision
within 1 year [4]. Risk factors for loss of vision were
active neovascularization, concomitant vitreous hemor-
rhage and progression of the detachment. Tractional de-
tachment involving or threatening the fovea is an indi-
cation for surgery. Eyes with recent circumscribed foveal
detachment may have a good recovery of visual function
(Fig. 2). Eyes with long-standing and widespread retinal
detachment have a very poor functional prognosis, even
if surgery is anatomically successful. Thus, it may be
wise to avoid attempts at surgery with poor expectations
and potential complications [12].
Laser treatment induces fibrotic regression of active
neovascularizations. This fibrosis may exert increased
tractive forces on the retina. Therefore, laser treatment
may accelerate the development of tractional retinal de-
tachment [8]. Eyes with extensive active fibrovascular
proliferations should therefore be closely observed after
photocoagulation. If laser treatment cannot be applied
because of blood or fibrovascular tissue covering the
retina, if regression of new vessels is not sufficient after
laser treatment, or if traction is progressive, early vitreous
surgery should be considered, before macular detachment
develops.
Combined tractional and rhegmatogenous retinal de-
tachment occurs if the contracting force of the fibrovas-
cular complexes creates retinal tears (Fig. 3). This type of
retinal detachment is rapidly progressive, the detached
retina is more mobile and may attain a bullous and convex
shape. Prompt surgery is usually necessary [29]. Techni-
cally this type of surgery may be demanding, because of
difficulties separating the fibrovascular complexes from
the mobile detached retina.
Fig. 2 a Tractional detachment of the macula. A fibrotic membrane
has contracted, and pulled the retina over the optic disc and created
a tractional retinal detachment of the macula. b One week after
vitrectomy, removal of the preretinal membranes, and endolaser the
retina is flattened. Visual acuity later improved to 0.6
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Diffuse macular edema
Fibrovascular membranes exerting traction on the central
retina may cause tractive macular edema. Surgical re-
moval of these membranes is the treatment of choice for
tractive diabetic macular edema (Fig. 1). Diabetic macu-
lar edema without visible traction is generally treated with
photocoagulation. While focal diabetic macular edema
responds well to focal laser treatment, the results of grid
laser treatment for diffuse diabetic macula edema are
unsatisfactory. Eyes with a detached posterior vitreous
have a lower risk of developing diffuse macular edema
[24]. Therefore vitreous detachment has been induced
surgically as an attempt to treat diffuse diabetic macular
edema. Indeed, a subgroup of eyes with a taut premacular
posterior hyaloid seemed to benefit from vitrectomy [26].
This strategy has been further developed with the intro-
duction of peeling of the internal limiting membrane for
the treatment of diffuse diabetic macular edema [10]. It is
however still controversial whether this approach really
improves vision in these eyes. From the pathophysiolog-
ical point of view, this procedure could relieve the ret-
ina from tractive forces, not visible biomicroscopically,
caused by the preretinal vitreous and the internal limiting
membrane. Optical coherence tomography (OCT) will
possibly facilitate the visualization of the vitreoretinal
interface and the identification of eyes with diffuse mac-
ula edema that should benefit from surgery. Another
mechanism of action for vitrectomy in diffuse macular
edema may be an improved supply of oxygen and nutri-
ents from the vitreous cavity to the macula. Moreover, the
taut condensed posterior premacular hyaloid may prevent
the diffusion and cause the accumulation of cytokines
produced by the ischemic retina which may lead to a
diffuse breakdown of the inner blood-retinal barrier. After
vitrectomy and ILM peeling these cytokines may escape
easier into the vitreous cavity. Combinations of the me-
chanical surgical approach with pharmacological ap-
proaches (e.g., intravitreal triamcinolone) may further
improve success rates for the treatment of diffuse diabetic
macular edema [17].
Avoiding complications of surgery
The main goals of vitreoretinal surgery in diabetic reti-
nopathy is to remove media opacities, completely relieve
all tractional adhesions, and to apply adequate laser
treatment to the retina. Two approaches can be used to
remove the fibrovascular membranes. With the “delami-
nation” or “en bloc” techniques the adhesions between the
membrane and the retina are severed with horizontal
cutting scissors and the membrane is removed in one
piece. The “segmentation” technique involves cutting the
membrane between two areas of adhesion with vertically
cutting scissors. The remaining stumps are trimmed with
the vitreous cutter [28]. Intravitreal gas tamponade and
laser treatment can be used in cases where small retinal
defects occur during preparation of the membranes.
Liquid silicone provides a permanent endotamponade
of the vitreous cavity. It can be used in eyes with recur-
rent hemorrhage after vitrectomy to obtain a clear optic
axis [14]. In eyes with multiple and large retinal defects,
which can easily occur during preparation of tightly ad-
hering membranes to a thin atrophic retina, liquid silicone
may keep the retina attached. In this setting it is partic-
ularly important to remove all tractional tissue from the
retina. Liquid silicone must not be used to push a trac-
tively detached retina flat against the pigment epithelium
and must not replace complete dissection of fibrovascular
tissue. It is assumed that water-soluble growth factors
reach high concentrations in the thin fluid film between
retina and the silicone bubble. Therefore, under silicone
there is probably an increased tendency for fibrovascular
reproliferations [22].
Another indication for silicone is progressive anterior
segment neovascularization, especially in aphacic and
vitrectomized eyes [1]. In these eyes easy access for
growth factors from the ischemic retina to the iris may
lead to aggressive iris neovascularization. Instillation of
liquid silicone prevents the easy diffusion from the retina
to the anterior segment and in combination with intra-
operative photocoagulation is an effective treatment op-
tion for progressive anterior segment neovascularization.
A serious complication of vitrectomy for diabetic ret-
inopathy is the progression of iris rubeosis and the de-
velopment of neovascular glaucoma [20]. Pathophysio-
logically two mechanisms are involved in the develop-
ment of this complication. In eyes with active preretinal
neovascularization these new vessels contribute to the
Fig. 3 a Tractive rhegmatogenous retinal detachment with a small
tear created by tractional strands
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supply of oxygen and nutrients to the inner retina. Sur-
gical removal of these new vessels will aggravate retinal
ischemia and stimulate the production of growth factors.
Moreover, removal of the vitreous provides an easier
diffusion of growth factors produced by the ischemic
retina to the anterior segment of the eye and will increase
the risk for anterior segment neovascularization. It is
therefore important to extensively treat the ischemic ret-
ina with endolaser, especially in eyes where active pre-
retinal neovascularizations are surgically removed [13]. If
the retina is edematous, laser effects may be difficult to
apply. Here it is helpful to inject perfluorcarbon liquids
into the eye. Under perfluorocarbons the application of
effective laser treatment to an edematous retina is much
easier.
The management of the lens during and after vitreous
surgery in diabetic eyes has changed considerably during
the last decades. Complete removal of the anterior vitre-
ous is not easily possible in phacic eyes and cataract
develops rapidly after vitrectomy. The lens was therefore
commonly removed intracapsularly during vitreous sur-
gery. This procedure, however, led to a high rate of
postoperative complications, especially the development
of neovascular glaucoma [3]. The mechanism was prob-
ably the easy access of growth factors from the ischemic
retina to the iris in an aphacic vitrectomized eye. If pos-
sible, intracapsular removal of the lens should therefore
be avoided in diabetic eyes. Some surgeons successfully
perform standard small incision extracapsular phaco-
emulsification with intraocular lens implantation simul-
taneously with vitreous surgery. The advantage of this
combined procedures is to avoid a second surgical pro-
cedure and to allow more complete vitrectomy [19].
Posterior capsular opacification may occur earlier in vit-
rectomized diabetic eyes; primary posterior capsulotomy
can therefore be considered if a combined vitreous and
cataract surgery is performed. Disadvantages of the
combined procedure may be an increased postoperative
inflammatory response in the anterior segment with fi-
brinous exudation, precipitates on the IOL and formation
of synechiae compared to a two-step procedure [27].
Limitations of surgery
With current advances in instrumentation, surgical skills,
improved understanding of the pathophysiology, and
supplementary medical drug treatment, vitreous surgery is
approaching its limits in diabetic retinopathy. Surgery can
safely clear media opacities and release traction on the
retina in most cases. Postoperative complications such as
severe intraocular inflammation and worsening of diffuse
macular edema may be prevented by supplementary in-
travitreal pharmacotherapy. Intravitreal steroids have an-
tiinflammatory and antiproliferative activity as well as the
potential to dry out macular edema. Reliable efficacy and
safety data on its use, however, are still to be provided.
Fibrovascular reproliferation is a severe problem but
rarely occurs if some basic rules are followed. The most
significant problem in diabetic retinopathy is the va-
soocclusive microvascular disease. Disappointing func-
tional results after anatomically successful surgery are
unfortunately common and are mostly due to retinal
ischemia. No surgical approach so far enables effective
reperfusion of occluded retinal capillaries. Our goals in
the treatment of diabetic retinopathy must focus on stra-
tegies that prevent severe complications [5, 7, 30] and
therefore on making ourselves as vitreous surgeons dis-
pensable.
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